Medicine News and Research

RSS

Studies raise questions about the role and responsibilities of patients on medication safety

In a new study to asses patient awareness of medications prescribed during a hospital visit, 44% of patients believed they were receiving a medication they were not, and 96% were unable to recall the name of at least one medication that they had been prescribed during hospitalization. These findings are published today in the Journal of Hospital Medicine.

10 Dec 2009

Researchers dispel myths on increased incidence of autism disorder

There has been a major increase in the number of children diagnosed with autistic spectrum disorders over the last two decades - the question is why? Researchers have found a sharp difference between the beliefs of ordinary people and medical experts about the reasons for the increased incidence of autism.

10 Dec 2009

Study reveals increased discussion on flu vaccines has no significant impact on public's behavior

Seasonal flu vaccination rates among American adults have only slightly improved over last year, despite increased public discussion of the importance of influenza vaccines resulting from the worldwide outbreak of the H1N1 virus.

10 Dec 2009

Pharma IQ to organize Anti-Infectives Summit in Philadelphia

Organized by Pharma IQ, a division of IQPC, the Anti-Infectives Summit will be held January 25-27, 2010 in Philadelphia, PA (www.anti-infectivesummit.com). This forum explores recent advances within anti-infective drug discovery and development, and is geared towards Chief Scientific Officers and Scientists working in microbiology, immunology, infectious diseases, medicinal chemistry and drug development.

From IQPC Ltd 10 Dec 2009

Arrayit Diagnostics signs exclusive License Agreement with Wayne State University

Arrayit Diagnostics, Inc., a majority-owned subsidiary of Arrayit Corporation (OTC Bulletin Board: ARYC), today announced that it has signed an exclusive License Agreement with Wayne State University to key intellectual property covering discoveries of biomarkers of ovarian cancer.

10 Dec 2009

National Heart Lung and Blood Institute of NIH awards Grand Opportunities grant to BMC

Boston Medical Center (BMC), today announced that it has been awarded a Grand Opportunities (GO) grant by the National Heart Lung and Blood Institute of the National Institutes of Health (NIH).

9 Dec 2009

Preliminary study shows 'mini' stem cell transplantation may safely reverse severe sickle cell disease

Results of a preliminary study by scientists at the National Institutes of Health and Johns Hopkins show that "mini" stem cell transplantation may safely reverse severe sickle cell disease in adults.

9 Dec 2009

Misuse of blood thinners in dialysis patients reported

Reuters/ABC News reports on research published in the Journal of the American Medical Association that examined the misuse of two blood thinners - Lovenox and Integrilin - in "about 20 percent of kidney dialysis patients who undergo a procedure to open a blocked artery [who] are given the wrong blood clot medicine, increasing the chances of significant bleeding, researchers said Tuesday.

9 Dec 2009

NPH acquires an exclusive license from UCLA for a suite of supramolecular nanoparticle technologies

NanoPacific Holdings, Inc. (NPH) announces the acquisition of an exclusive license from University of California at Los Angeles (UCLA) for a suite of supramolecular nanoparticle technologies. Under the terms of the agreement between NPH and UCLA, NPH will have an exclusive worldwide license of a system composed of a ternary mixture of modular components that self-assemble into supramolecular nanoparticles.

9 Dec 2009

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

Watson Pharmaceuticals, Inc. today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® (silodosin) for up to 52 weeks of treatment. RAPAFLO® is an effective and uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), the number one reason patients visit urologists.

9 Dec 2009

CIDR utilizes Isilon scale-out NAS for genotyping and statistical genetics services

Isilon Systems today announced that the Center for Inherited Disease Research (CIDR) at Johns Hopkins University is using Isilon scale-out NAS to power its leading-edge genotyping and statistical genetics services, which generate up to three terabytes of new data per day.

9 Dec 2009

Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented

Sangamo BioSciences, Inc. announced today the presentation of preliminary data from the Phase 2 clinical trial of its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for amyotrophic lateral sclerosis (ALS) at a Work in Progress session at the 20th International Symposium on ALS/MND held in Berlin, Germany.

9 Dec 2009

Risk of serious injury at summer camps is low compared to other popular youth activities

Although a trip to summer camp is highly anticipated by over 11 million children and adults each year, sending a child off to summer camp can be a source of anxiety for parents. Findings from a new study published in the December issue of Injury Prevention should ease their concerns however.

9 Dec 2009

2009 Ward Burdick Award for UAB Director

The director of the University of Alabama at Birmingham (UAB) Center for Metabolic Bone Disease has won the 2009 Ward Burdick Award for Distinguished Service to Clinical Pathology from the American Society for Clinical Pathology (ASCP).

9 Dec 2009

Laser technique used to change metal colors could have important implications for medicine

University of Rochester optics professor Chunlei Guo made headlines in the past couple of years when he changed the color of everyday metals by scouring their surfaces with precise, high-intensity laser bursts.

9 Dec 2009

Human blood stem cells can be engineered to kill HIV and other chronic viral diseases

Researchers from the UCLA AIDS Institute and colleagues have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells - a process that potentially could be used against a range of chronic viral diseases.

9 Dec 2009

Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma

Oxagen Limited, a drug discovery and development company specializing in inflammation, today announced that the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its lead oral CRTH2 (DP2) antagonist, has now been completed.

9 Dec 2009

Medicine News and Research

Studies raise questions about the role and responsibilities of patients on medication safety

Researchers dispel myths on increased incidence of autism disorder

Study reveals increased discussion on flu vaccines has no significant impact on public's behavior

Pharma IQ to organize Anti-Infectives Summit in Philadelphia

Arrayit Diagnostics signs exclusive License Agreement with Wayne State University

National Heart Lung and Blood Institute of NIH awards Grand Opportunities grant to BMC

Preliminary study shows 'mini' stem cell transplantation may safely reverse severe sickle cell disease

Misuse of blood thinners in dialysis patients reported

NPH acquires an exclusive license from UCLA for a suite of supramolecular nanoparticle technologies

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

CIDR utilizes Isilon scale-out NAS for genotyping and statistical genetics services

Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented

Risk of serious injury at summer camps is low compared to other popular youth activities

2009 Ward Burdick Award for UAB Director

Laser technique used to change metal colors could have important implications for medicine

Human blood stem cells can be engineered to kill HIV and other chronic viral diseases

Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma

Report highlights the state of oral health for children and adults in the United States

Research article on Peliosis hepatis

New Acesis software platform improves patient safety and quality care

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News